Ionis Pharmaceuticals Announced Topline Data From HALOS Phase 1/2A Open-label Study Of ION582 In Angelman Syndrome, ION582 Was Safe And Well Tolerated In The Study And Showed Encouraging And Consistent Benefits
Ionis Pharmaceuticals Announced Topline Data From HALOS Phase 1/2A Open-label Study Of ION582 In Angelman Syndrome, ION582 Was Safe And Well Tolerated In The Study And Showed Encouraging And Consistent Benefits
Ionis Pharmaceuticals 公布了 HALOS 针对 ION582 的 1/2A 期开放标签研究的主要数据，该研究显示 ION582 安全且耐受性良好，并显示出令人鼓舞且持续的益处
- ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients
- ION582 was safe and well tolerated at all dose levels
- Ionis plans to move ION582 into pivotal trial
- Detailed ION582 data to be presented at upcoming medical meeting
- ION582 显示 Angelman 综合征患者的多个功能领域持续改善
- ION582 在所有剂量水平下均安全且耐受性良好
- Ionis 计划将 ION582 转入关键试验
- 详细的 ION582 数据将在即将举行的医学会议上公布
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。